Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article discusses the modern societal obsession with body perfection and its impact on body dissatisfaction, escalating demand for aesthetic techniques, and advertising, without reporting new research findings.

In this study, the researchers evaluated the exposure-response relationship of ritlecitinib on eyebrow and eyelash regrowth and concluded that the established models justify selecting a 50 mg dose for patients with severe alopecia areata, while highlighting differing efficacy among evaluation methods.

This case report highlights a rare association between congenital triangular alopecia and vitiligo, noting that treatment with tofacitinib improved the patient's vitiligo but not the alopecia.

This case report describes a 15-year-old Japanese girl with juvenile hypothyroidism who developed hypertrichosis and hyperkeratosis due to a keratin plug inhibiting hair growth on her back and arms.

In this study, the authors suggest that patient safety with isotretinoin in Palestine can be improved by adapting pharmacy and medical practice protocols to better educate patients and ensure adherence to safety monitoring and laboratory ordering.

This study estimated the economic burden of alopecia areata in Romania for 2022, finding costs of 46.289 million EUR for adult and 1.89 million EUR for pediatric cases.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

This article reviews acromegaloid facial appearance syndrome and presents a case in a 57-year-old woman, emphasizing the need for more cases to understand its clinical features and inheritance patterns.

This study found that baricitinib can counteract the cytokine-driven reduction of the enzyme PADI1 in human keratinocytes, which may help improve skin barrier function in atopic dermatitis by enabling epidermal differentiation.

This case report describes an 11-month-old infant with Biotinidase deficiency who exhibited multifocal seizures, neuroregression, alopecia, and skin issues, highlighting prompt diagnosis and the dramatic clinical response to biotin treatment.

This case report describes a child with alopecia areata and atopic dermatitis who showed significant improvement after treatment with baricitinib and corticosteroid ointment, suggesting their potential efficacy and safety.

This case report describes repigmentation and curling of hair in a patient undergoing acitretin therapy.

In this case report, a 40-year-old male with alopecia universalis and twenty-nail dystrophy showed significant nail improvement and partial hair regrowth after six months of baricitinib treatment, improving his quality of life.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study found that platelet-rich plasma treatments improved quality of life for patients with pattern hair loss, as measured by decreased HAIRDEX scores in several domains over 3-5 months.

This study indicates potential differences in the hair spectra of individuals with mood disorders, suggesting a promising, yet preliminary, method for noninvasive prediagnosis.

Panitumumab can cause excessive ear hair growth.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

This research highlights that alopecia, while not physically harmful, significantly impacts individuals' mental health due to its effects on self-image, and suggests a management strategy that includes psychological counseling alongside dermatological treatment to address these challenges.

This chapter reviews the causes, diagnosis, and treatment of hirsutism and related androgen excess conditions in women, presenting no novel clinical findings.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

This study found that both intralesional PRP and corticosteroids are effective for alopecia areata, but PRP offers higher patient satisfaction and fewer side effects, despite a slower initial response.

This source reports that while effective treatments for hereditary hypotrichosis simplex have been limited, recent studies show promising results using interventions such as minoxidil, topical gentamicin, and platelet-rich plasma injections.

In this phase 2a study of adults with alopecia areata, researchers observed that ritlecitinib treatment did not result in significant differences in brainstem auditory evoked potential changes or axonal swelling compared to placebo, suggesting the dog toxicity findings may not be clinically relevant in humans.

In this retrospective study of eight Saudi children with hereditary vitamin D resistant rickets, researchers observed that adjunctive cinacalcet appeared safe and showed initial promise in improving serum PTH levels, though further investigation is needed to confirm its efficacy.

This case report details an occurrence of PRIDE syndrome accompanied by lumbosacral hypertrichosis.

This case study reports that carbimazole therapy led to significant hair regrowth and a drop in thyrotropin receptor antibody levels in an 11-year-old girl diagnosed with alopecia areata and Graves' disease.

This article presents a case of a seventeen-year-old female with dermatopathia pigmentosa reticularis and emphasizes the importance of distinguishing its clinical features from other similar disorders, supported by dermoscopic and histopathological findings.